A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 13 Apr 2018
At a glance
- Drugs Selonsertib (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Registrational; Therapeutic Use
- Acronyms STELLAR 4
- Sponsors Gilead Sciences
- 13 Apr 2018 According to a Gilead Sciences media release, data from this trial is expected in the first half of 2019.
- 25 Mar 2018 This trial has been completed in Portugal.
- 23 Feb 2018 Planned End Date changed from 1 Oct 2023 to 1 Nov 2022.